Loading
HLA-A is the molecule that holds up short pieces of a cell's proteins for T cells to inspect. Engineered T-cell receptor therapies such as tebentafusp and afami-cel only work in people with the HLA-A*02 variant, because the receptor recognises the tumour peptide sitting in that particular groove. This dossier gathers the 4 products (2 approved), 7 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
The antigen-presentation pathway record describes the escape routes: tumours that lose beta-2-microglobulin or HLA stop showing peptides and become invisible to CD8 T cells and to these therapies, and the HLA genotype shapes which mutations are visible at all.
| Modality | Approved | Phase 3 | Phase 2 |
|---|---|---|---|
| Cell therapy 2 | - | ||
| T-cell engager 2 | - |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
PRISM-MEL-301 NCT06112314 | 3 | Recruiting | Untreated HLA-A*02:01-positive advanced cutaneous melanoma: brenetafusp + nivolumab vs nivolumab-based regimens | - | |
| 3 | Recruiting | Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM) | - | ||
| 2 | Active | A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | - | ||
IGNYTE-ESO NCT03967223 | 2 | Positive | Advanced synovial sarcoma or myxoid/round cell liposarcoma, NY-ESO-1+, HLA-A*02+: lete-cel (single arm) | ORR 42%. | |
IMCgp100-202 NCT03070392 | 2 | Positive | Untreated HLA-A*02:01-positive metastatic uveal melanoma: tebentafusp vs investigator's choice (pembrolizumab, ipilimumab, or dacarbazine) | OS 21.7 vs 16.0 months; HR 0.51. | |
| 1/2 | Active | Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers | - | ||
SPEARHEAD-3 Pediatric Study NCT05642455 | 1/2 | Recruiting | A Phase 1/2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects With MAGE-A4 Positive Tumors | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"HLA-A" OR ABSTRACT:"HLA-A" OR TITLE:"HLA-A*02" OR ABSTRACT:"HLA-A*02" OR TITLE:"HLA-A*02:01" OR ABSTRACT:"HLA-A*02:01" OR TITLE:"major histocompatibility complex, class I, A" OR ABSTRACT:"major histocompatibility complex, class I, A") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HLA-A, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/hla-a.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/hla-a.json. Licence CC BY-NC 4.0.